cathepsin

(redirected from Cathepsin S)
Also found in: Dictionary, Medical.
Related to Cathepsin S: Cathepsin L

cathepsin

[kə′thep·sən]
(biochemistry)
Any of several proteolytic enzymes occurring in animal tissue that hydrolyze high-molecular-weight proteins to proteoses and peptones.
References in periodicals archive ?
10, Presentation time 8:00 AM C 12:00 PM (local time) Authors: Leslie Holsinger, Alex Marquez, Teresa Mixcoalt-Zecuatl, David Karpf, Anantha Sudhakar, Jeffrey Dener, Kyle Elrod, Robert Booth and Nigel A Calcutt Title: Development of a Cathepsin S Inhibitor for Neuropathic Pain: Efficacy in a Preclinical Model of Taxol-Induced Neuropathy and Phase 1 Clinical Profile
Published prelinical data suggest that cathepsin S inhibition may provide a therapeutic benefit in patients with dermatological disorders such as psoriasis.
Celera's cathepsin S inhibitor, CRA-028129, entered a Phase I trial in September 2005 in a single center study being conducted at the Christchurch Clinical Studies Trust (CSST) in Christchurch, New Zealand.
Published preclinical data suggest that cathepsin S inhibition may provide a therapeutic benefit in patients with a variety of painful disorders, including neuropathic pain.
The acquisition of the Cathepsin S project is consistent with Medivir's ambition to enhance the commercial potential of our protease inhibitor portfolio.
We're pleased with the progress we've made in advancing our cathepsin S inhibitor through to this clinical development stage as a potential new treatment for psoriasis.
We believe that a small molecule inhibitor of Cathepsin S will provide a useful approach to treating certain inflammatory conditions and we are pleased by J&JPRD's advancement of a compound from our collaboration into development," said Bob McDowell, Ph.
Celera Genomics (NYSE:CRA), an Applera Corporation business, today announced that the company had received an additional research milestone payment from Aventis Pharma, the pharmaceutical company of Aventis (NYSE:AVE), as part of the Cathepsin S inhibitor collaboration between the companies.
Initiated in May 2002, the collaboration is focused on the discovery of small molecule enzyme inhibitors targeting Cathepsin S, an enzyme involved in the activation of T-cells.
Medivir and Peptimmune, a business unit of Genzyme General, jointly announce today that, an orally active, small molecule inhibitor of the protease enzyme Cathepsin S, suppresses the development of arthritis in an animal disease model.
March 29 /PRNewswire/ -- Medivir and Peptimmune jointly announce today that an orally active, small molecule inhibitor of the protease enzyme Cathepsin S has been selected as a Candidate Drug (CD).
and Medivir today announced the issuance of a European patent claiming uses of Cathepsin S inhibitors in therapeutic formulations for suppressing immune responses.